1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. TAIWAN PAIN MANAGEMENT DRUGS MARKET BY DRUG TYPE
5.1. Introduction
5.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
5.3. Corticosteroids
5.4. Acetaminophen
5.5. Opioid
5.5.1. Strong Opioid
5.5.2. Weak Opioid
5.6. Antidepressants
5.7. Anticonvulsant Drugs
5.8. Others
6. TAIWAN PAIN MANAGEMENT DRUGS MARKET BY DISTRIBUTION CHANNEL
6.1. Introduction
6.2. Hospital Pharmacies
6.3. Retail Pharmacies
6.4. Online Pharmacies
7. TAIWAN PAIN MANAGEMENT DRUGS MARKET BY INDICATION
7.1. Introduction
7.2. Cancer
7.3. Rheumatoid Arthritis
7.4. Chronic Back Pain
7.5. Post-Operative Pain
7.6. Others
8. COMPETITIVE ENVIRONMENT AND ANALYSIS
8.1. Major Players and Strategy Analysis
8.2. Market Share Analysis
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Competitive Dashboard
9. COMPANY PROFILES
9.1. Novartis Pharmaceuticals Corporation (Novartis AG)
9.2. Pfizer Inc.
9.3. GlaxoSmithKline plc
9.4. Sanofi S.A
9.5. Viatris Inc.
9.6. Abbott Laboratories
9.7. Lumosa Therapeutics Co., Ltd.
9.8. Shionogi Inc.
10. APPENDIX
10.1. Currency
10.2. Assumptions
10.3. Base and Forecast Years Timeline
10.4. Key benefits for the stakeholders
10.5. Research Methodology
10.6. Abbreviations